Study S000629

Effect of Subcutaneous Semaglutide 2.4 mg Once-weekly Compared to Placebo in Subjects With Obesity and Knee Osteoarthritis

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05064735
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: COMPLETED
Enrollment: 407
Start: 2021-10-01
Primary completion: 2023-07-24
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:semaglutide 2.4 mg; DRUG:semaglutide 2.4 mg (placebo)
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1246-5824; EUDRACT_NUMBER:2020-000204-11

Registered primary outcomes

Percentage Change in Body Weight [Baseline (week 0), end of treatment (week 68)]
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score [Baseline (week 0), end of treatment (week 68)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007372	Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. Bliddal H, The New England journal of medicine	2024	Randomized trial	PMID 39476339 DOI	cites ClinicalTrials.gov:NCT05064735; registry reference RESULT:39476339